An observational study in Incidence of Thyroid Cancer in Long Standing MNG, sponsored by University of Khartoum. Completed at 1 site in Sudan. Per ClinicalTrials.gov, last updated 2024-05-09.
Sponsored by University of Khartoum · Observational
To determine the incidence of thyroid cancer in patients with long standing goitres presenting for surgery.
This is a prospective cohort study The objective is to determine the incidence of cancer in patients with long standing goitres( more than 10 years ) who present for surgery in Khartoum Teaching Hopspital - Sudan.
Introduction: goitre is endemic in Sudan with prevalence ranging between 5-42% in different regions of the country. Patients are referred for surgery only if they develop pressure symptoms.
The incidence of thyroid carcinoma is high in endemic goitrous areas. Determining the risk of cancer in patient with long standing goitres may help in early early referral and early surgical intervention.
Methods: This is prospective cohort study including 160 patients with long standing goitrers of 10 years or more who presented from March 2017 to September 2017 to Khartoum Teaching Hospital-Sudan
Patients with long standing goitres presenting for surgery in Khartoum Teaching Hospital March 2017-September 2018
Exclusion Criteria:
Patients with long standing multinodular goitres of 10years or more presenting to surgical unit in Khartoum Teaching Hospital -Sudan. Checking incidence of malignancy in this group.
Diagnostic Test: Histopathology
Thyroidectomy for patients and histological examination of specimen to determine incidence of malignancy.
Rate of malignancy
Rate of malignancy in resected goitre specimens
Time frame: March 2017-September 2018
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Khartoum